U.S. markets closed

Sunniva Inc. (SNNVF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1150+0.0150 (+15.00%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1000
Open0.1399
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1000 - 0.1400
52 Week Range0.0610 - 1.2200
Volume43,844
Avg. Volume30,607
Market Cap5.301M
Beta (5Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Sunniva Inc. And CannaPharmaRx, Inc. Announce Extension To Outside Date Of Share Purchase Agreement For Sale Of Sunniva Medical Inc.
    PR Newswire

    Sunniva Inc. And CannaPharmaRx, Inc. Announce Extension To Outside Date Of Share Purchase Agreement For Sale Of Sunniva Medical Inc.

    Sunniva Inc. ("Sunniva", the "Company", "we", "our" or "us") (CSE:SNN, OTCQB:SNNVF) and CannaPharmaRx Canada Corp. ("CannaPharmaRx"), a subsidiary of CannaPharmaRx, Inc. (OTC Pink: CPMD) today jointly announce that they are extending the outside date of the Share Purchase Agreement previously announced on June 11, 2019 with respect to the sale of the shares of Sunniva Medical Inc. ("SMI") to CannaPharmaRx (the "SMI Transaction") until December 20, 2019. The terms of the SMI Transaction, as amended on October 2, 2019, otherwise remain unchanged, with the purchase price to be satisfied by way of CAD $16.0 million in cash (less outstanding indebtedness of SMI at closing) and CAD $4.0 million by way of a promissory note of CannaPharmaRx (the "CPMD Note"). The Company and CannaPharmaRx continue to work as expeditiously as possible to complete the transaction on or prior to the amended outside date.

  • Sunniva Inc. Announces Q3 2019 Financial Results And Dispute Related To Cathedral City Glasshouse
    PR Newswire

    Sunniva Inc. Announces Q3 2019 Financial Results And Dispute Related To Cathedral City Glasshouse

    Sunniva Inc. ("Sunniva", the "Company", "we", "our" or "us") (CSE:SNN) (OTCQB:SNNVF), a North American provider of cannabis products and services, today released its financial results and management's discussion and analysis for the three and nine months ended September 30, 2019. All figures are reported in Canadian dollars ($), unless otherwise indicated. Sunniva's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS"). The Company also reports receipt of a 30-day notice of termination under its build to suit lease for the Cathedral City Glasshouse and notices of default regarding funding of the facility.

  • Benzinga

    Sunniva President, Board Director Resign Weeks After CFO Departure

    Cannabis company  Sunniva Inc.  (CSE: SNN) (OTC: SNNVF ) said Monday that President Kevin Wilkerson has resigned for personal reasons. Wilkerson also resigned from his position as president and CEO of ...